Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase II, Multicenter, Two Cohort Study of 160 mg Osimertinib in EGFR T790M-Positive Non-Small Cell Lung Cancer Patients With Brain Metastases or Leptomeningeal Disease Who Progressed on Prior EGFR TKI TherapyAnn. Oncol 2020 Jul 04;[EPub Ahead of Print], S Park, MH Lee, M Seong, ST Kim, JH Kang, BC Cho, KH Lee, EK Cho, JM Sun, SH Lee, JS Ahn, K Park, MJ Ahn
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.